Clinical Trial Update: Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System. [Phase 2]

View source ↗

Summary

Phase 2 trial investigating tislelizumab plus lenvatinib and gemox for potentially resectable locally advanced malignant tumors of the biliary system.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary System Malignancies
• Biliary Tract Cancer

Drugs mentioned

• GEMOX (gemcitabine + oxaliplatin)
• Lenvatinib (lenvatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Potentially Resectable Locally Advanced Malignant Tumors of Biliary System | Phase 2 | Status: UNKNOWN